Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Treatment Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05372354
What this trial is testing

Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 260
Testing effectiveness (Phase 2)Study completedNCT00482495
What this trial is testing

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 42
Testing effectiveness (Phase 2)Study completedNCT03320330
What this trial is testing

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Who this might be right for
Recurrent Malignant Solid NeoplasmRecurrent OsteosarcomaRefractory Malignant Solid Neoplasm+1 more
Children's Oncology Group 26
Testing effectiveness (Phase 2)Study completedNCT00960739
What this trial is testing

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma

Who this might be right for
Neuroblastoma
Centre Oscar Lambret 30
Testing effectiveness (Phase 2)Study completedNCT00945139
What this trial is testing

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Who this might be right for
Ovarian Cancer
New Mexico Cancer Research Alliance 46
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439357
What this trial is testing

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 4
Post-approval studies (Phase 4)Study completedNCT01171365
What this trial is testing

Small Particle Steroids in Refractory Asthma

Who this might be right for
Asthma
University of Nottingham 30
Testing effectiveness (Phase 2)Study completedNCT00062075
What this trial is testing

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+5 more
National Cancer Institute (NCI) 47
Not applicableWithdrawnNCT00770419
What this trial is testing

Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersDepression+7 more
Rutgers, The State University of New Jersey
Testing effectiveness (Phase 2)Study completedNCT00063219
What this trial is testing

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Who this might be right for
Carcinoma, Non-Small-Cell LungLung Neoplasms
Wyeth is now a wholly owned subsidiary of Pfizer 48
Large-scale testing (Phase 3)Temporarily pausedNCT00382395
What this trial is testing

SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma

Who this might be right for
GlaucomaGlaucoma, Open Angle
SOLX, Inc. 180
Testing effectiveness (Phase 2)Study completedNCT00433381
What this trial is testing

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Who this might be right for
Adult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Neoplasm
National Cancer Institute (NCI) 123
Testing effectiveness (Phase 2)Study completedNCT01121406
What this trial is testing

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Boehringer Ingelheim 110
Testing effectiveness (Phase 2)Ended earlyNCT01904253
What this trial is testing

Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

Who this might be right for
Small Cell Lung Cancer (SCLC)
Taiho Oncology, Inc. 18
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Early research (Phase 1)Looking for participantsNCT06208735
What this trial is testing

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Who this might be right for
B-Cell LeukemiaNon-Hodgkin's LymphomaB-cell Acute Lymphoblastic Leukemia+5 more
British Columbia Cancer Agency 24
Testing effectiveness (Phase 2)Looking for participantsNCT04961515
What this trial is testing

Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

Who this might be right for
Primary Central Nervous System Hodgkin Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine 19
Testing effectiveness (Phase 2)UnknownNCT02537977
What this trial is testing

CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy

Who this might be right for
LeukemiaLymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine 60
Large-scale testing (Phase 3)Study completedNCT00478777
What this trial is testing

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene Corporation 150
Testing effectiveness (Phase 2)UnknownNCT03337919
What this trial is testing

ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
University College, London 78
Next Page